By Richard Lenti
The use of a synthetic marijuana derivative in treating multiple sclerosis (MS) is being questioned after the first major non-commercial study of its main active ingredient, tetrahydrocannabinol (THC), found the drug had little effect in slowing the course of the disease.
Researchers in England enrolled nearly 500 patients over an eight year span. People with progressive MS received either THC capsules or a placebo for three years to see how their MS changed over this period.
Overall, the study found no evidence to support the effectiveness of THC on MS progression, using either a disability scale administered by neurologists or a patient reported scale measuring the drug’s impact.
There was some evidence to suggest a beneficial effect in patients at the lower end of the disability scale, but the benefit was only found in a small group of people rather than the whole population.
Read more at National Pain Report.
(0) Readers Comments
November 12, 2012
October 08, 2012
September 12, 2012
July 23, 2012
June 11, 2019
April 01, 2019
March 18, 2019
Oh boy...Your right we hate to hear this. You know why people in pain
Doesn't the 1.5 billion is spent a year give credence to its possitive
Many MS drugs cause PML and deaths too these drugs all need t
I knew him when he was breaking in at a couple of Los Angeles TV stati
Saying there is a 'twist' is the worst type of spoile